证券代码：600771 证券简称：广誉远 编号：临 2024-039 4、公司全体监事承诺 2024 年第三季度报告所载资料不存在任何虚假记载、误导性 陈述或重大遗漏，并对其内容的真实性、准确性和完整性承担个别及连带责任。 特此公告。 广誉远中药股份有限公司 第八届监事会第十次会议决议公告 特别提示 本公司监事会及全体监事保证本公告内容不存在任何虚假记载、误导性陈述或者重 大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 广誉远中药股份有限公司第八届监事会第十次会议于 2024 年 10 月 15 日以电话、 邮件及其他网络通讯方式发出通知，于 2024 年 10 月 25 日以通讯方式召开。会议应出 席监事 3 名，亲自出席监事 3 名，符合《公司法》及《公司章程》的有关规定。会议由 监事会主席张华中主持，经认真审议，以"同意 3 票，反对 0 票，弃权 0 票"的表决结 果全票通过了《公司 2024 年第三季度报告》。 监事会对《公司 2024 年第三季度报告》进行了审慎审核，认为： 1、公司 2024 年第三季度报告的编制和审议程序符合法律法规、公司章程和公司内 部管理制度的规定。 2、公司 2 ...

证券代码：600771 证券简称：广誉远 编号：临 2024-038 广誉远中药股份有限公司（以下简称"公司"）第八届董事会第十二次会议于 2024 年 10 月 15 日以电话、邮件及其他网络通讯方式向全体董事发出通知，于 2024 年 10 月 25 日以通讯方式召开。会议应出席董事 6 名，实际出席董事 6 名，符合《公司法》及 《公司章程》的有关规定。会议由董事长李晓军主持，经大会认真审议，通过了以下议 案： 一、审议通过《公司 2024 年第三季度报告》 《公司 2024 年第三季度报告》已经董事会审计委员会审议通过，同意将该报告提 交公司董事会审议。 表决情况：同意 6 票，反对 0 票，弃权 0 票。 具体内容详见公司同日在上海证券交易所网站披露的《公司2024年第三季度报告》。 二、审议通过《广誉远中药股份有限公司舆情管理制度（试行）》 广誉远中药股份有限公司 第八届董事会第十二次会议决议公告 特别提示 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或者重 大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 为了完善公司内部管理制度体系，提高公司应对各类舆情的规范管理 ...

Group 1: Product Overview - The company's core products, Gui Ling Ji and Ding Kun Dan, have significant therapeutic effects and are positioned for both health maintenance and treatment [4][5][6]. - Gui Ling Ji is suitable for a wide range of chronic conditions, including over a hundred diseases such as rheumatism, gout, and osteoporosis, enhancing memory and restoring bodily functions [3][4]. - Ding Kun Dan targets women's health, focusing on regulating menstrual cycles and improving overall vitality, with over 5,000 cases collected for clinical research [4][5]. Group 2: Market Strategy - The company is actively collecting treatment cases and conducting targeted marketing strategies to better match consumer needs [4][5]. - Innovative marketing strategies include cultural exploration, digital transformation, and resource collaboration to enhance brand influence and market competitiveness [4][5]. - The company emphasizes brand building and cultural heritage to engage younger consumers and rejuvenate the brand's image [5][6]. Group 3: Financial Performance - The company reported a net profit of over 150 million in other income for the first half of 2024, compared to over 190 million for the entire previous year [8][9]. - The inventory value as of mid-2024 was 694 million, accounting for 44.6% of net assets, reflecting a 21.82% increase from the previous year [14]. - Sales expenses have decreased from 70.11% in 2022 to 44.7% in the first half of 2024, indicating improved cost management [14]. Group 4: Regulatory and Product Development - The company is exploring the possibility of converting Gui Ling Ji from a prescription drug to an OTC product, which requires full disclosure of the formula and compliance with national policies [9][10]. - The unique production techniques of An Gong Niu Huang Wan have been recognized as a national intangible cultural heritage, enhancing its market position [6][7]. - The company is cautious about disclosing proprietary formulas due to their classified status, which impacts its ability to market certain products [10][11]. Group 5: Future Plans and Challenges - The company is focusing on the revitalization of Gui Jiu (turtle wine) and has established a dedicated wine production and marketing company to enhance operational efficiency [8][9]. - There are plans to expand product offerings and explore international markets, although current regulations limit overseas sales [13][14]. - The company aims to improve employee training and attract external talent to enhance operational efficiency and market communication [12][13].

证券代码：600771 证券简称：广誉远 编号：临 2024-036 广誉远中药股份有限公司 关于控股股东首次增持公司股份暨后续增持计划的公告 特别提示 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或者 重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： 公司于 2024 年 8 月 26 日收到控股股东神农科技集团《关于增持广誉远股票的告知 函》，现将有关情况公告如下： 1 首次增持情况：2024 年 8 月 26 日，广誉远中药股份有限公司（以下简称"公司" "广誉远"）控股股东神农科技集团有限公司（以下简称"神农科技集团"）通 过集中竞价方式增持了公司股票 389,100 股，占公司总股本的 0.079%，本次增 持成交总额 6,427,360 元（不含手续费）。 增持计划基本情况：基于对公司未来发展的信心和长期投资价值的认可，为提 升投资者信心，切实维护中小股东利益和市场稳定，神农科技集团拟实施广誉 远股票增持计划，以更好地支持广誉远未来持续、稳定、健康的发展。神农科 技集团计划自 2024 年 8 月 26 日起 12 个月内，以集中竞价、大宗交易等符合 ...

证券代码：600771 证券简称：广誉远 编号：临 2024-035 广誉远中药股份有限公司 1 会议召开时间：2024 年 08 月 30 日（星期五）15:00-16:00 会议召开地点：价值在线（www.ir-online.cn） 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或者 重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： 一、说明会类型 广誉远中药股份有限公司（以下简称"公司"）已于 2024 年 8 月 23 日披露了《2024 年半年度报告》及《2024 年半年度报告摘要》。为便于广大投资者更加全面深入地了解 公司经营业绩、发展战略及财务状况等情况，公司定于 2024 年 08 月 30 日（星期五） 15:00-16:00 在"价值在线"（www.ir-online.cn）举办广誉远中药股份有限公司 2024 关于召开 2024 年半年度业绩说明会的预告公告 特别提示 会议召开方式：网络文字互动方式 会议问题征集：投资者可于 2024 年 08 月 28 日 15：00 前通过访问网址 https://eseb.cn/1haVHfXY33a ...

养生精品中药 始于1541 2023 环境 社会及治理报告 Environmental Social and Governance Report | Produce of I Ad I Ad I January of Art I Jan Landers | | --- | | 1.2 公司治理 加强完善 | | 1.3 利益相关方沟通 | | 1.4 实质性议题识别 | | 1.5 实质性议题矩阵 | | 1.6 廉洁合规 构筑底线 | | 1.7 守护网络 保护隐私 | 2 3 关于本报告 【报告说明 《广誉远中药股份有限公司 2023 年度环境、社会及治理报告》（以下简称"ESG 报告""本报告"）是广誉远中药股份有限 公司第一份 ESG 报告，旨在向各利益相关方真实、客观地展示公司在环境、社会和治理方面所采取的行动和达到的成效，系 统地回应利益相关方的期望和要求，促进公司更好发展的同时，积极履行社会责任。 [ 时间范围 ( 发布周期 本报告为年度报告。 [ 报告称谓 为便于表述和阅读，报告中"广誉远中药股份有限公司"也以"广誉远""公司"或"我们"表示。 数据说明 本报告使用数据来源包括公司实际运行的原 ...

证券代码：600771 证券简称：广誉远 编号：临 2024-034 广誉远中药股份有限公司 3、在提出本意见之前，监事会未发现参与半年报编制和审议的人员有违反保密规 定的行为。 4、公司全体监事承诺 2024 年半年度报告所载资料不存在任何虚假记载、误导性陈 述或重大遗漏，并对其内容的真实性、准确性和完整性承担个别及连带责任。 1 特此公告。 第八届监事会第九次会议决议公告 特别提示 本公司监事会及全体监事保证本公告内容不存在任何虚假记载、误导性陈述或者重 大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 广誉远中药股份有限公司第八届监事会第九次会议于 2024 年 8 月 12 日以电话、邮 件及其他网络通讯方式发出通知，于 2024 年 8 月 22 日以现场方式在山西省晋中市太谷 区广誉远路 1 号山西广誉远国药有限公司会议室召开。会议应出席监事 3 名，亲自出席 监事 3 名，符合《公司法》及《公司章程》的有关规定。会议由监事会主席张华中主持， 经认真审议，以"同意 3 票，反对 0 票，弃权 0 票"的表决结果全票通过了《公司 2024 年半年度报告及摘要》。 监事会对《广誉远中药股份有限 ...

广誉远中药股份有限公司（以下简称"公司"）第八届董事会第十一次会议于 2024 年 8 月 12 日以电话、邮件及其他网络通讯方式向全体董事发出通知，于 2024 年 8 月 22 日在山西省晋中市太谷区广誉远路 1 号山西广誉远国药有限公司会议室以现场结合通 讯方式召开。会议应出席董事 7 名，实际出席董事 7 名，其中董事季占璐、刘兆维及独 立董事赵选民通过通讯方式参会。公司全体监事及高管列席了会议，符合《公司法》及 《公司章程》的有关规定。会议由董事长李晓军主持，经大会认真审议，通过了以下议 案： 一、审议通过《公司 2023 年度环境、社会及治理（ESG）报告》 为切实履行好国有企业社会责任，提高公司核心竞争力，有效推进上市公司可持续 发展目标，公司编制了《广誉远中药股份有限公司 2023 年度环境、社会及治理（ESG） 报告》。 表决情况：同意 7 票，反对 0 票，弃权 0 票。 证券代码：600771 证券简称：广誉远 编号：临 2024-033 广誉远中药股份有限公司 第八届董事会第十一次会议决议公告 特别提示 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或者重 大遗漏， ...

Financial Performance - The company reported a significant increase in revenue, achieving a total of 1.2 billion CNY for the first half of 2024, representing a year-on-year growth of 15%[8]. - The company's operating revenue for the first half of 2024 was ¥659.6 million, a decrease of 4.90% compared to ¥693.6 million in the same period last year[13]. - Net profit attributable to shareholders was ¥59.6 million, an increase of 13.75% from ¥52.4 million in the previous year[13]. - The net cash flow from operating activities decreased by 41.74% to ¥162.3 million, primarily due to increased raw material prices and timely payments to suppliers[16]. - Basic earnings per share rose to ¥0.12, reflecting a 9.09% increase from ¥0.11 in the same period last year[14]. - The company's total assets decreased by 9.20% to ¥2.39 billion from ¥2.63 billion at the end of the previous year[13]. - The company's total operating revenue for the first half of 2024 was CNY 659.60 million, a decrease of 4.90% compared to CNY 693.56 million in the same period last year[54]. - Operating costs decreased by 12.21% to ¥164.34 million from ¥187.19 million year-on-year[54]. - The company reported a net loss reduction from CNY 608,674,316.23 to CNY 549,071,264.90, indicating an improvement in financial performance[123]. Market Expansion and Strategy - User data indicates a growth in active customers, with the number reaching 2 million, an increase of 25% compared to the same period last year[8]. - The company has provided a positive outlook for the second half of 2024, projecting a revenue growth of 20% based on current market trends and product demand[8]. - New product launches are expected to contribute an additional 300 million CNY in revenue, with a focus on herbal supplements and traditional medicine innovations[8]. - The company is expanding its market presence, targeting an increase in distribution channels by 30% across major cities in China by the end of 2024[8]. - A strategic acquisition of a local herbal product manufacturer is in progress, which is anticipated to enhance the company's product portfolio and market share[8]. - The company is focusing on the development of new products and technologies, particularly in the area of traditional Chinese medicine formulations[28]. - The company is actively integrating online e-commerce, internet medical services, and traditional Chinese medicine culture to create a comprehensive business ecosystem[47]. Research and Development - The company is investing 50 million CNY in research and development for new technologies in traditional medicine, aiming to improve product efficacy and safety[8]. - Research and development expenses increased by 11.99% to ¥17.94 million compared to ¥16.02 million in the previous year[54]. - The company has 22 ongoing R&D projects focused on enhancing product academic promotion and clinical research data[50]. - The company is actively pursuing the development of classic formulas and the restoration of dormant varieties to enhance long-term competitiveness[50]. Regulatory and Compliance Issues - The company has faced regulatory challenges, including a notice from the China Securities Regulatory Commission regarding information disclosure violations, which may impact investor confidence[3]. - The company is closely monitoring regulatory changes in the pharmaceutical sector to ensure compliance and adapt to new market conditions[28]. - The company has implemented measures to ensure compliance with market regulations and prevent price manipulation in the raw material market[65]. - The company has been under investigation by the China Securities Regulatory Commission since December 2023 for suspected violations of information disclosure laws[104]. Environmental and Sustainability Efforts - The company has implemented a third-party environmental monitoring scheme, focusing on wastewater and air emissions, to ensure compliance with environmental standards[78]. - The company has established a pollution emergency response plan, which was revised in February 2023 and filed with the local environmental bureau[77]. - The company has committed to measures to reduce carbon emissions, although specific effects were not disclosed[94]. - The company has established criteria for recognizing discontinued operations, which include components that represent a major business or geographical area that has been disposed of or classified as held for sale[196]. Legal Matters - The company is involved in a lawsuit regarding performance commitment compensation against Dongsheng Group, with the case registered at the Xi'an Intermediate People's Court as of June 20, 2024[99]. - The company has been actively pursuing legal actions to recover debts from various parties, including a claim of 190,562.67 yuan against Shanghai Ciji Pharmaceutical Co., Ltd.[102]. - The company received a fine of 8 million yuan from the Shanxi Securities Regulatory Bureau for information disclosure violations[104]. - The company has not fulfilled court judgments totaling RMB 7.8262 million and RMB 215,800 related to contract disputes[106]. Corporate Governance - The company has committed to improving its corporate governance structure and comply with regulations regarding related transactions[97]. - The company has established an independent financial department and accounting system to ensure compliance with relevant laws and regulations[96]. - The company held its annual general meeting on June 28, 2024, where several key reports and proposals were approved, including the three-year shareholder return plan[67]. - The company experienced changes in its board of directors, with the election of Wang Jijun as an independent director following the resignation of several key executives[68]. Shareholder Information - As of the report date, the total number of ordinary shareholders was 67,350, with the largest shareholder, Jinchuang Investment Co., Ltd., holding 71,508,968 shares, representing 14.61% of the total shares[115]. - The top three shareholders include Jinchuang Investment Co., Ltd. (14.61%), Jiang Shibo (1.67%), and Xi'an Dongsheng Group Co., Ltd. (0.90%) as of the report date[115]. - The company has not reported any changes in share capital structure during the reporting period[114]. - The company has not disclosed any significant asset acquisitions or sales during the reporting period[109].

北京海润天睿律师事务所 对本法律意见书的出具,本所律师特作如下声明: 1. 本所律师仅就本次会议的召集、召开程序、出席会议人员的资格、召集 人资格、表决程序、表决结果发表意见,不对本次会议所审议的议案内容及该等 议案所表述的事实或数据的真实性、准确性和完整性发表意见; 2023 年年度股东大会的法律意见书 致:广誉远中药股份有限公司 北京海润天睿律师事务所(以下简称"本所")接受广誉远中药股份有限公 司(以下简称"公司")的委托,指派冯玫律师、陈媛律师出席公司 2023 年年度 股东大会,并依据《中华人民共和国公司法》(以下简称"《公司法》")、《中华人 民共和国证券法》(以下简称"《证券法》")、《上市公司股东大会规则》等法律、 法规和规范性文件及《公司章程》的规定,就公司本次股东大会的召集、召开程 序、出席会议人员的资格、召集人资格、表决程序、表决结果等有关事宜出具本 法律意见书。 关于广誉远中药股份有限公司 2．本所律师无法对网络投票过程进行见证，参与本次会议网络投票的股东 资格、网络投票结果均由相应的证券交易所交易系统和互联网投票系统予以认 证， 3. 本所律师已经按照《上市公司股东大会规则》的要求, ...